Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avutometinib and Defactinib: First Approval.

Drugs - 1 Oct 2025

Blair Hannah A

Abstract excerpt

Avutometinib and defactinib (AVMAPKI™ FAKZYNJA™ CO-PACK) is a co-packaged rapidly accelerating fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibitor (avutometinib) and focal adhesion kinase (FAK)/proline-rich tyrosine kinase-2 (Pyk2) inhibitor (defactinib) being developed by Verastem Oncology for the treatment of RAS/MAPK pathway-driven cancers. In May 2025, avutometinib and defactinib was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Approval
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Mutation

Share to Ovarian Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 40762779
DOI: 10.1007/s40265-025-02215-8

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avutometinib and Defactinib: First Approval.PMID 40762779Read ↗

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.Semantic proximity Read ↗

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.Semantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerSemantic proximity Read ↗

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.Semantic proximity Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutationSemantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.Semantic proximity Read ↗

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.Semantic proximity Read ↗

Tovorafenib: First Approval.Semantic proximity Read ↗

Avapritinib: First Approval.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.